Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology

References

• Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, et al. The burden of respiratory syncytial virus infection in young children. N Eng J Med 2009; 360(6):588-98; PMID:19196675; http://dx.doi.org/10.1056/NEJMoa0804877
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious D, American Academy of Pediatrics Bronchiolitis Guidelines C. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134(2):e620-38; PMID:25070304; http://dx.doi.org/10.1542/peds.2014-1666
   PubMed Web of Science ®Google Scholar
• The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102(3):531-7; http://dx.doi.org/10.1542/peds.102.3.531
   Web of Science ®Google Scholar
• Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolescent Med 2011; 165(6):498-505. Epub 2011/02/09; PMID:21300647
   PubMedGoogle Scholar
• Lofland JH, Touch SM, O'Connor JP, Chatterton ML, Moxey ED, Paddock LE, Nash DB, Desai SA. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Therapeutics 2000; 22(11):1357-69; PMID:11117660; http://dx.doi.org/10.1016/S0149-2918(00)83032-5
   PubMed Web of Science ®Google Scholar
• Nuijten MJC, Wittenberg W, Lebmeier M. Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children: A UK Analysis. Pharmaco Economics 2007; 25(1):55-71; PMID:17192118; http://dx.doi.org/10.2165/00019053-200725010-00006
   PubMed Web of Science ®Google Scholar
• Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assessment (Winchester, England) 2008; 12(36): iii, ix-x:1-86. Epub 2008/12/04
   Web of Science ®Google Scholar
• Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. J Medical Economics 2012; 15(5):987-96. Epub 2012/05/12; PMID:22574798; http://dx.doi.org/10.3111/13696998.2012.690013
   PubMedGoogle Scholar
• Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC, 3rd, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 1994; 68(8):5321-5. Epub 1994/08/01; PMID:8035532
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89(4):422-34; PMID:4305198
   PubMed Web of Science ®Google Scholar
• Olson MR, Varga SM. Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert Rev Vaccines 2008; 7(8):1239-55; PMID:18844597; http://dx.doi.org/10.1586/14760584.7.8.1239
   PubMed Web of Science ®Google Scholar
• Openshaw PJM, Tregoning JS. Immune Responses and Disease Enhancement during Respiratory Syncytial Virus Infection. Clin Microbiol Rev 2005; 18(3):541-55; PMID:16020689; http://dx.doi.org/10.1128/CMR.18.3.541-555.2005
   PubMed Web of Science ®Google Scholar
• Prince GA, Jenson AB, Hemming VG, Murphy BR, Walsh EE, Horswood RL, Chanock RM. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol 1986; 57(3):721-8. Epub 1986/03/01; PMID:2419587
   PubMed Web of Science ®Google Scholar
• Vaux-Peretz F, Chapsal J, Meignier B. Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice. Vaccine 1992; 10(2):113-8; PMID:1539464; http://dx.doi.org/10.1016/0264-410X(92)90027-H
   PubMed Web of Science ®Google Scholar
• De Swart RL, Kuiken T, Timmerman HH, van Amerongen G, Van Den Hoogen BG, Vos HW, Neijens HJ, Andeweg AC, Osterhaus AD. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J Virol 2002; 76(22):11561-9. Epub 2002/10/22; PMID:12388717; http://dx.doi.org/10.1128/JVI.76.22.11561-11569.2002
   PubMed Web of Science ®Google Scholar
• Lindell DM, Morris SB, White MP, Kallal LE, Lundy PK, Hamouda T, Baker JR Jr, Lukacs NW. A Novel Inactivated Intranasal Respiratory Syncytial Virus Vaccine Promotes Viral Clearance without Th2 Associated Vaccine-Enhanced Disease. PLoS One 2011; 6(7):e21823; PMID:21789184; http://dx.doi.org/10.1371/journal.pone.0021823
   PubMed Web of Science ®Google Scholar
• Schmitz N, Kurrer M, Bachmann MF, Kopf M. Interleukin-1 Is Responsible for Acute Lung Immunopathology but Increases Survival of Respiratory Influenza Virus Infection. J Virol 2005; 79(10):6441-8; PMID:15858027; http://dx.doi.org/10.1128/JVI.79.10.6441-6448.2005
   PubMed Web of Science ®Google Scholar
• Prince GA, Potash L, Horswood RL, Camargo E, Suffin SC, Johnson RA, Chanock RM. Intramuscular inoculation of live respiratory syncytial virus induces immunity in cotton rats. Infect Immun 1979; 23(3):723-8.; PMID:572342
   PubMed Web of Science ®Google Scholar
• Delgado M, Coviello S, Monsalvo A, Melendi G, Hernandez J, Batalle J. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009; 15:34-41; PMID:19079256; http://dx.doi.org/10.1038/nm.1894
   PubMed Web of Science ®Google Scholar
• Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, Sattentau QJ, Openshaw PJ. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 2006; 12(8):905-7. Epub 2006/07/25; PMID:16862151; http://dx.doi.org/10.1038/nm1456
   PubMed Web of Science ®Google Scholar
• Gauger PC, Vincent AL, Loving CL, Henningson JN, Lager KM, Janke BH, Kehrli ME, Jr, Roth JA. Kinetics of lung lesion development and pro-inflammatory cytokine response in pigs with vaccine-associated enhanced respiratory disease induced by challenge with pandemic (2009) A/H1N1 influenza virus. Veterinary Pathol 2012; 49(6):900-12. Epub 2012/03/31; PMID:22461226; http://dx.doi.org/10.1177/0300985812439724
   PubMed Web of Science ®Google Scholar
• Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, Henningson J, Vincent AL, Golding H. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Translational Med 2013; 5(200):200ra114. Epub 2013/08/30; PMID:23986398; http://dx.doi.org/10.1126/scitranslmed.3006366
   PubMed Web of Science ®Google Scholar
• Vincent AL, Lager KM, Janke BH, Gramer MR, Richt JA. Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine. Veterinary Microbiol 2008; 126(4):310-23. Epub 2007/08/28; PMID:17719188; http://dx.doi.org/10.1016/j.vetmic.2007.07.011
   PubMed Web of Science ®Google Scholar
• Bendelja K, Gagro A, Bace A, Lokar-Kolbas R, Krsulovic-Hresic V, Drazenovic V. Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demonstrated by cytokine flow cytometry. Clin Exp Immunol 2000; 121:332-8; PMID:10931150; http://dx.doi.org/10.1046/j.1365-2249.2000.01297.x
   PubMed Web of Science ®Google Scholar
• Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JLL, Bont L. Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants. N Eng J Med 2013; 368(19):1791-9; PMID:23656644; http://dx.doi.org/10.1056/NEJMoa1211917
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Figueras-Aloy J, Law BJ, Group IRIpVRSS. Identifying Risk Factors for Severe Respiratory Syncytial Virus Among Infants Born After 33 Through 35 Completed Weeks of Gestation: Different Methodologies Yield Consistent Findings. Pediatr Infect Dis J 2004; 23(11):S193-S201.; PMID:15577573; http://dx.doi.org/10.1097/01.inf.0000144664.31888.53
   PubMedGoogle Scholar
• Christiaansen AF, Knudson CJ, Weiss KA, Varga SM. The CD4 T cell response to respiratory syncytial virus infection. Immunol Res 2014; 59(1-3):109-17. Epub 2014/05/20; PMID:24838148; http://dx.doi.org/10.1007/s12026-014-8540-1
   PubMed Web of Science ®Google Scholar
• Research CfBEa. Vaccine Safety & Availability - Common Ingredients in US. Licensed Vaccines. 2015
   Google Scholar
• Flach TL, Ng G, Hari A, Desrosiers M, Zhang P, Ward SM, Seamone ME, Vilaysane A, Mucsi AD, Fong Y, et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011; 17(4):479-87; PMID:21399646; http://dx.doi.org/10.1038/nm.2306
   PubMed Web of Science ®Google Scholar
• Neuzil K, Johnson J, Tang Y, Prieels J, Slaoui M, Gar N, Graham BS. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine 1997; 15(5):525-32; PMID:9160520; http://dx.doi.org/10.1016/S0264-410X(97)00218-1
   PubMed Web of Science ®Google Scholar
• Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134(2):e620-38. Epub 2014/07/30; PMID:25070304; http://dx.doi.org/10.1542/peds.2014-1666
   PubMed Web of Science ®Google Scholar
• Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 2010; 28(3):840-8. Epub 2009/10/20; PMID:19835829; http://dx.doi.org/10.1016/j.vaccine.2009.10.019
   PubMed Web of Science ®Google Scholar
• Falsey A, Walsh E, Capellan J, Gravenstein S, Zambon M, Yau E, Gorse GJ, Edelman R, Hayden FG, McElhaney JE, et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines-nonadjuvanted vaccine or vaccine adjuvanted with alum-given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis 2008; 198(9):1317-26; PMID:18855558; http://dx.doi.org/10.1086/592168
   PubMed Web of Science ®Google Scholar
• Cherukuri A, Stokes K, Patton K, Kuo H, Sakamoto K, Lambert S, Stillman E, Moore ML, Lee S. An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice. Immunity Ageing 2012; 9(1):21; PMID:23031690; http://dx.doi.org/10.1186/1742-4933-9-21
   PubMed Web of Science ®Google Scholar
• Knudson CJ, Hartwig SM, Meyerholz DK, Varga SM. RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets. PLoS Pathog 2015; 11(3):e1004757. Epub 2015/03/15; PMID:25769044; http://dx.doi.org/10.1371/journal.ppat.1004757
   PubMed Web of Science ®Google Scholar
• Derscheid RJ, Gallup JM, Knudson CJ, Varga SM, Grosz DD, van Geelen A, Hostetter SJ, Ackermann MR. Effects of Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) in the Perinatal Lamb Model of RSV. PLoS One 2013; 8(12):e81472; PMID:24324695; http://dx.doi.org/10.1371/journal.pone.0081472
   PubMed Web of Science ®Google Scholar
• Hem SL, Johnston CT, HogenEsch H. Imject® Alum is not aluminum hydroxide adjuvant or aluminum phosphate adjuvant. Vaccine 2007; 25(27):4985-6; PMID:17543429; http://dx.doi.org/10.1016/j.vaccine.2007.04.078
   PubMed Web of Science ®Google Scholar
• Grun JL, Maurer PH. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: The role of endogenous interleukin 1 in proliferative responses. Cellular Immunol 1989; 121(1):134-45; http://dx.doi.org/10.1016/0008-8749(89)90011-7
   PubMed Web of Science ®Google Scholar
• Ghimire TR. The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm. SpringerPlus 2015; 4:181. Epub 2015/05/02; PMID:25932368; http://dx.doi.org/10.1186/s40064-015-0972-0
   PubMed Web of Science ®Google Scholar
• Honda-Okubo Y, Saade F, Petrovsky N. Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine. 2012; 30(36):5373-81. Epub 2012/06/26; PMID:22728225; http://dx.doi.org/10.1016/j.vaccine.2012.06.021
   PubMed Web of Science ®Google Scholar
• Gordon DL, Sajkov D, Woodman RJ, Honda-Okubo Y, Cox MM, Heinzel S, Petrovsky N. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant. Vaccine 2012; 30(36):5407-16. Epub 2012/06/22; PMID:22717330; http://dx.doi.org/10.1016/j.vaccine.2012.06.009
   PubMed Web of Science ®Google Scholar
• Bielefeldt-Ohmann H, Prow NA, Wang W, Tan CS, Coyle M, Douma A, Hobson-Peters J, Kidd L, Hall RA, Petrovsky N. Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals. Veterinary Res 2014; 45:130. Epub 2014/12/18; PMID:25516480; http://dx.doi.org/10.1186/s13567-014-0130-7
   PubMed Web of Science ®Google Scholar
• Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol 2015; 89(6):2995-3007. Epub 2014/12/19; PMID:25520500; http://dx.doi.org/10.1128/JVI.02980-14
   PubMed Web of Science ®Google Scholar
• Honda-Okubo Y, Barnard D, Ong CH, Peng B-H, Tseng C-TK, Petrovsky N. Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology. J Virol 2015; 89(6):2995-3007; PMID:25520500; http://dx.doi.org/10.1128/JVI.02980-14
   PubMed Web of Science ®Google Scholar
• Harris K, Ream R, Gao J, Eichelberger M. Intramuscular immunization of mice with live influenza virus is more immunogenic and offers greater protection than immunization with inactivated virus. Virol J 2011; 8(1):251; PMID:21600020; http://dx.doi.org/10.1186/1743-422X-8-251
   PubMed Web of Science ®Google Scholar
• San-Juan-Vergara H, Sampayo-Escobar V, Reyes N, Cha B, Pacheco-Lugo L, Wong T, Peeples ME, Collins PL, Castaño ME, Mohapatra SS. Cholesterol-Rich microdomains as docking platforms for respiratory syncytial virus in normal human bronchial epithelial cells. J Virol 2012; 86(3):1832-43; PMID:22090136; http://dx.doi.org/10.1128/JVI.06274-11
   PubMed Web of Science ®Google Scholar
• Wong TM, Boyapalle S, Sampayo V, Nguyen HD, Bedi R, Kamath SG, Moore ML, Mohapatra S, Mohapatra SS. Respiratory syncytial virus (rsv) infection in elderly mice results in altered antiviral gene expression and enhanced pathology. PLoS One 2014; 9(2):e88764
   PubMed Web of Science ®Google Scholar
• Boyapalle S, Wong T, Garay J, Teng M, San Juan-Vergara H, Mohapatra S, Mohapatra S. Respiratory syncytial virus NS1 protein colocalizes with mitochondrial antiviral signaling protein MAVS following infection. PLoS One 2012; 7(2):e29386; PMID:22383950; http://dx.doi.org/10.1371/journal.pone.0029386
   PubMed Web of Science ®Google Scholar
• Cooper PD, Petrovsky N. Delta inulin: a novel, immunologically active, stable packing structure comprising β-D-[2 -> 1] poly(fructo-furanosyl) α-D-glucose polymers. Glycobiology 2011; 21(5):595-606. Epub 2010/12/15; PMID:21147758; http://dx.doi.org/10.1093/glycob/cwq201
   PubMed Web of Science ®Google Scholar
• Empey KM, Orend JG, Peebles RS, Jr, Egaña L, Norris KA, Oury TD, Kolls JK. Stimulation of Immature Lung Macrophages with Intranasal Interferon Gamma in a Novel Neonatal Mouse Model of Respiratory Syncytial Virus Infection. PLoS One 2012; 7(7):e40499; PMID:22792355; http://dx.doi.org/10.1371/journal.pone.0040499
   PubMedGoogle Scholar
• Fuentes S, Crim RL, Beeler J, Teng MN, Golding H, Khurana S. Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection. Vaccine 2013; 31(37):3987-94. Epub 2013/06/08; PMID:23742994; http://dx.doi.org/10.1016/j.vaccine.2013.05.088
   PubMed Web of Science ®Google Scholar
• McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, et al. Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody. Science 2013; 340(6136):1113-7; PMID:23618766; http://dx.doi.org/10.1126/science.1234914
   PubMed Web of Science ®Google Scholar
• Connors M, Kulkarni AB, Firestone CY, Holmes KL, Morse HC, 3rd, Sotnikov AV, Murphy BR. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol 1992; 66(12):7444-51. Epub 1992/12/01; PMID:1433525
   PubMed Web of Science ®Google Scholar
• Walsh E, Falsey AR. Humoral and Mucosal Immunity in Protection from Natural Respiratory Syncytial Virus Infection in Adults. J Infect Dis 2004; 190(2):373-8; PMID:15216475; http://dx.doi.org/10.1086/421524
   PubMed Web of Science ®Google Scholar
• Walsh EE, Peterson DR, Kalkanoglu AE, Lee FE-H, Falsey AR. Viral Shedding and Immune Responses to Respiratory Syncytial Virus Infection in Older Adults. J Infect Dis 2013; 207(9):1424-32; PMID:23382572; http://dx.doi.org/10.1093/infdis/jit038
   PubMed Web of Science ®Google Scholar
• Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991; 163(4):693-8. Epub 1991/04/01; PMID:2010624; http://dx.doi.org/10.1093/infdis/163.4.693
   PubMed Web of Science ®Google Scholar
• Hall CB, Walsh EE, Schnabel KC, Long CE, McConnochie KM, Hildreth SW, Anderson LJ. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis 1990; 162(6):1283-90. Epub 1990/12/01; PMID:2230258; http://dx.doi.org/10.1093/infdis/162.6.1283
   PubMed Web of Science ®Google Scholar
• Matsuoka M, Yoshida K, Maeda T, Usuda S, Sakano H. Switch circular DNA formed in cytokine-treated mouse splenocytes: evidence for intramolecular DNA deletion in immunoglobulin class switching. Cell 1990; 62(1):135-42; PMID:2114219; http://dx.doi.org/10.1016/0092-8674(90)90247-C
   PubMed Web of Science ®Google Scholar
• Yoshimoto T, Paul WE. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 1994; 179(4):1285-95. Epub 1994/04/01; PMID:7908323; http://dx.doi.org/10.1084/jem.179.4.1285
   PubMed Web of Science ®Google Scholar
• Nagarajan NA, Kronenberg M. Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J Immunol 2007; 178(5):2706-13. Epub 2007/02/22; PMID:17312112; http://dx.doi.org/10.4049/jimmunol.178.5.2706
   PubMed Web of Science ®Google Scholar
• Brown DM, Roman E, Swain SL. CD4 T cell responses to influenza infection. Semin Immunol 2004; 16(3):171-7; PMID:15130501; http://dx.doi.org/10.1016/j.smim.2004.02.004
   PubMed Web of Science ®Google Scholar
• Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383(6603):787-93; PMID:8893001; http://dx.doi.org/10.1038/383787a0
   PubMed Web of Science ®Google Scholar
• Parker DC. T cell-dependent B cell activation. Annu Rev Immunol 1993; 11:331-60; PMID:8476565; http://dx.doi.org/10.1146/annurev.iy.11.040193.001555
   PubMed Web of Science ®Google Scholar
• Lobigs M, Pavy M, Hall RA, Lobigs P, Cooper P, Komiya T, Toriniwa H, Petrovsky N. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J General Virol 2010; 91(Pt 6):1407-17; PMID:20130134; http://dx.doi.org/10.1099/vir.0.019190-0
   PubMed Web of Science ®Google Scholar
• Layton RC, Petrovsky N, Gigliotti AP, Pollock Z, Knight J, Donart N, Pyles J, Harrod KS, Gao P, Koster F. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. Vaccine 2011; 29(37):6242-51. Epub 2011/07/09; PMID:21736913; http://dx.doi.org/10.1016/j.vaccine.2011.06.078
   PubMed Web of Science ®Google Scholar
• Cristillo AD, Ferrari MG, Hudacik L, Lewis B, Galmin L, Bowen B, Thompson D, Petrovsky N, Markham P, Pal R. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol 2011; 92(Pt 1):128-40. Epub 2010/12/21; PMID:21169215; http://dx.doi.org/10.1099/vir.0.023242-0
   PubMed Web of Science ®Google Scholar
• Eckersley A.M. PN, Kinne J, Wernery R, Wernery U. Improving the dromedary antibody response: The hunt for the ideal camel adjuvant. J Camel Practice Res 2011; 18(1):30-46
   Google Scholar
• Töpfer E, Boraschi D, Italiani P. Innate Immune Memory: The latest frontier of adjuvanticity. J Immunol Res 2015; 2015:7
   Web of Science ®Google Scholar
• Rodriguez-Del Rio E, Marradi M, Calderon-Gonzalez R, Frande-Cabanes E, Penades S, Petrovsky N, Alvarez-Dominguez C. A gold glyco-nanoparticle carrying a Listeriolysin O peptide and formulated with Advax delta inulin adjuvant induces robust T-cell protection against listeria infection. Vaccine 2015; 33(12):1465-73. Epub 2015/02/11; PMID:25659269; http://dx.doi.org/10.1016/j.vaccine.2015.01.062
   PubMed Web of Science ®Google Scholar
• Polack FP, Teng MN, L.Collins P, Prince GA, Exner M, Regele H, Lirman DD, Rabold R, Hoffman SJ, Karp CL, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002; 196(6):859-65; PMID:12235218; http://dx.doi.org/10.1084/jem.20020781
   PubMed Web of Science ®Google Scholar
• Crabtree TD, Jin L, Raymond DP, Pelletier SJ, Houlgrave CW, Gleason TG, Pruett TL, Sawyer RG. Preexposure of Murine Macrophages to CpG oligonucleotide results in a biphasic tumor necrosis factor alpha response to subsequent lipopolysaccharide challenge. Infect Immun 2001; 69(4):2123-9; PMID:11254566; http://dx.doi.org/10.1128/IAI.69.4.2123-2129.2001
   PubMed Web of Science ®Google Scholar
• Ito S, Pedras-Vasconcelos J, Klinman DM. CpG oligodeoxynucleotides increase the susceptibility of normal mice to infection by candida albicans. Infect Immun 2005; 73(9):6154-6; PMID:16113339; http://dx.doi.org/10.1128/IAI.73.9.6154-6156.2005
   PubMed Web of Science ®Google Scholar
• Prince GA, Mond JJ, Porter DD, Yim KC, Lan SJ, Klinman DM. Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J Virol 2003; 77(24):13156-60; PMID:14645572; http://dx.doi.org/10.1128/JVI.77.24.13156-13160.2003
   PubMed Web of Science ®Google Scholar
• Chang RK, Chen A. Impact of palivizumab on rsv hospitalizations for children with hemodynamically significant congenital heart disease. Pediatr Cardiol 2010; 31(1):90-5; PMID:19915892; http://dx.doi.org/10.1007/s00246-009-9577-0
   PubMed Web of Science ®Google Scholar
• Clementi N, Mancini N, Solforosi L, Castelli M, Clementi M, Burioni R. Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens. Int J Mol Sci 2012; 13(7):8273-92; PMID:22942702; http://dx.doi.org/10.3390/ijms13078273
   PubMed Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Jr, Connor EM, Sondheimer HM. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143(4):532-40; PMID:14571236; http://dx.doi.org/10.1067/S0022-3476(03)00454-2
   PubMed Web of Science ®Google Scholar